Paul Brough joined the Company in 2001, having previously held a role at Knoll Pharmaceuticals. He has a keen interest in fragment- and structure-based drug discovery, and has led med chem programmes on several collaborated projects at Vernalis, from hit ID through to clinical lead status. He was instrumental in the early evaluation and successful implementation of off-rate screening as a new hit ID platform at Vernalis. He has co-authored several patents and publications, particularly in the field of Hsp90 molecular chaperone inhibitors and structurally-related kinases.
